deltatrials
Completed PHASE2 NCT00087074

CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor

A Trial of CCI-779 in Patients With Soft Tissue Sarcoma.

Sponsor: National Cancer Institute (NCI)

Conditions Gastrointestinal Stromal Tumor Recurrent Adult Soft Tissue Sarcoma Stage I Adult Soft Tissue Sarcoma Stage II Adult Soft Tissue Sarcoma Stage III Adult Soft Tissue Sarcoma Stage IV Adult Soft Tissue Sarcoma
Interventions laboratory biomarker analysis temsirolimus
Updated 6 times since 2017 Last updated: Jun 3, 2013 Started: Jun 30, 2004 Primary completion: Dec 31, 2005

Listed as NCT00087074, this PHASE2 trial focuses on Gastrointestinal Stromal Tumor and Recurrent Adult Soft Tissue Sarcoma and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 6 times since 2004, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Jun 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Rochester, United States